Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
New insights on ammonia emissions Calculated ammonia emissions in the Netherlands are still declining. However, emissions overall are greater than previously assumed.
Big Data gives more insight into the health impacts of air pollution Long-term exposure to particulate air pollution and nitrogen dioxide has been found to be associated with total mortality and mortality from respiratory diseases and lung cancer in the Netherlands.
Risk of degradation of European ecosystems by air pollution is decreasing The number of natural areas in Europe that are threatened by air pollution will decrease between 2005 and 2020.
Concerns over whooping cough despite modifications to vaccination programme Modifications to the National Immunisation Programme have led to fewer cases of whooping cough among children.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.
Regional differences in testing rates underestimate incidence of LGV epidemic Until 2003, Lymphogranuloma venereum (LGV), an aggressive form of chlamydia, was considered to be a rare tropical disease, endemic to Africa, Asia and the Caribbean.